Tarsus Pharmaceuticals Inc Ordinary Shares TARS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Reports Third Quarter 2026 Financial Results
Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
Tarsus to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $76.89
- Day Range
- $75.94–81.18
- 52-Week Range
- $53.89–91.53
- Bid/Ask
- $75.63 / $85.00
- Shares Outstanding
- 49.31M
- Market Cap
- $3.96B
- Volume/Avg
- 732,093 / 859,807
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.17
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 370
- Website
- https://www.tarsusrx.com
Valuation
Metric | TARS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 38.05 |
Price/Sales | 5.17 |
Price/Cash Flow | — |
Price/Earnings
TARS
Financial Strength
Metric | TARS |
|---|---|
Quick Ratio | 1.81 |
Current Ratio | 1.96 |
Interest Coverage | −86.87 |
Quick Ratio
TARS
Profitability
Metric | TARS |
|---|---|
Return on Assets (Normalized) | −116.28% |
Return on Equity (Normalized) | −219.81% |
Return on Invested Capital (Normalized) | −177.91% |
Return on Assets
TARS
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|%n@>^&v | LOCK|qL@dH | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|gnD$S% | LOCK|@>bPG | $99B | |||
| Moderna Inc MRNA | LOCK|m^ZxJ> | LOCK|td | $90B | |||
| argenx SE ADR ARGX | LOCK|QvW%#^ | LOCK|XR | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|<^&<&<r | LOCK|FQ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|<bVB!X^& | LOCK|pm%>G | $31B | |||
| Incyte Corp INCY | LOCK|@wlpCv | LOCK|VY< | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|dyl&#% | LOCK|#TGcx | $22B | |||
| BioNTech SE ADR BNTX | LOCK|%$NLkyg | LOCK|^>s | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|pNMQn! | LOCK|@ld | $16B |
United States